These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Early Experience with Video-Assisted Thoracoscopic Anatomic Segmentectomy.
    Author: Yao F, Wang J, Yao J, Xu L, Qian J, Cao Y.
    Journal: J Laparoendosc Adv Surg Tech A; 2018 Jul; 28(7):819-826. PubMed ID: 29424636.
    Abstract:
    BACKGROUND: Anatomic segmentectomy for stage I nonsmall cell lung cancer (NSCLC) has potential advantages such as preserving pulmonary function and reducing postoperative complications. However, many surgeons are deterred from this procedure for its anatomical complexity. Therefore, we presented our early experience with video-assisted thoracoscopic surgery (VATS) anatomic segmentectomy compared with our most recent VATS lobectomy cases. PATIENTS AND METHODS: Forty patients with cT1aN0M0 (ground-glass opacity [GGO] rate >50%) NSCLC underwent VATS segmentectomy from January 2015 to December 2016. To compare the short-term postoperative outcomes, 47 patients, who underwent VATS lobectomy for cT1aN0M0 NSCLC (GGO rate ≤50% and pure solid nodule) during the same period, were referred to as a control group. RESULTS: The two groups were similar in age, sex, preoperative pulmonary functional assessment, and associated comorbidities. The tumor size in the segmentectomy group was significantly smaller (median, 0.8 cm versus 1.4 cm, P < .001). Segmentectomy and lobectomy groups had similar operating time, estimated blood loss, duration of chest tube drainage, length of postoperative hospital stay, and postoperative major and minor morbidities. With regard to lymph node evaluation, lobectomy was associated with more lymph nodes (median, 12 versus 9 nodes, P < .001) and mediastinal nodal stations evaluated (median, 3 versus 3 stations, P < .001). CONCLUSIONS: With acceptable morbidity and mortality, VATS segmentectomy may be an acceptable option for the treatment of cT1aN0M0 (GGO rate >50%) NSCLC.
    [Abstract] [Full Text] [Related] [New Search]